The impact of COVID‐19 and vaccination status on outcomes in veterans with head and neck squamous cell carcinoma

Documenti analoghi

• Establishment of an in situ model to explore the tumor immune microenvironment in head and neck squamous cell carcinoma
  di: Congxian Lu, et al.
  Pubblicazione: (2024)
• Neutrophil‐to‐lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma
  di: Hiroki Morimoto, et al.
  Pubblicazione: (2024)
• Pretreatment fat‐free mass index correlates with early death in patients with head and neck squamous cell carcinoma
  di: Charbél Talani, et al.
  Pubblicazione: (2024)
• Survival and complications after carotid resection for head and neck squamous cell carcinoma: A systematic review and pooled analysis
  di: Gian Marco Pace, et al.
  Pubblicazione: (2024)
• Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study
  di: Julie E. Bauman, et al.
  Pubblicazione: (2024)